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To the Editor: Coxsackievirus 
A6 (CVA6) is a human enterovirus 
associated with herpangina in infants. 
In the winter of 2012, we evaluated a 
cluster of 8 patients, 4 months–3 years 
of age, who were brought for treatment 
at Boston Children’s Hospital (Boston, 
MA, USA) with a variant of hand, 
foot, and mouth disease (HFMD) 
that has now been linked to CVA6 
(Table, Appendix, wwwnc.cdc.gov/
EID/article/18/10/12-0813-T1.htm). 
During this same period, the Boston 
Public Health Commission’s syndromic 
surveillance system detected a 3.3-fold 
increase in emergency department 
discharge diagnoses of HFMD. In the 
United States, HFMD typically occurs 
in the summer and early autumn and 
is characterized by a febrile enanthem 
of oral ulcers and macular or vesicular 
lesions on the palms and soles; the 
etiologic agents are most often CVA16 
and enterovirus 71.
In contrast to the typical mani-
festation, the patients in the Boston 
cluster exhibited symptoms in 
late winter (Table, Appendix) and 
had perioral (Figure, panel A) and 
perirectal (Figure, panel B) papules 
and vesicles on the dorsal aspects 
of the hands and feet (Figure, panel 
C). Patients experienced a prodrome 
lasting 1–3 days, consisting of fever 
(8 patients), upper respiratory tract 
symptoms (4 patients), and irritability 
(7 patients). This prodrome was 
followed by the development of a 
perioral papular rash (8 patients), 
which was often impetiginized with 
secondary crusting; a prominent 
papulovesicular rash on the dorsum 
of the hands and feet (6 patients); 
and a perirectal eruption (7 patients). 
Half of the patients had intraoral 
lesions. Fever abated in most of the 
patients within a day after onset of 
the exanthem. The rash resolved over 
7–14 days with no residual scarring. 
Samples from the oropharynx, rectum, 
and vesicles from these patients were 
sent to the Centers for Disease Control 
and Prevention (Atlanta, GA, USA) 
for analysis. Reverse transcription 
PCR and sequencing by using primers 
specifi c for a portion of the viral 
protein 1 coding region identifi ed 
CVA6 (1) (Table, Appendix).
Outbreaks of HFMD caused 
by CVA6 have been described in 
Singapore, Finland, Taiwan, and 
most recently in Japan; most cases 
have occurred in the warmer months 
(2–6). Cases in the cluster described 
here are likely related to an emerging 
outbreak of CVA6-associated HFMD 
in the United States (7). The atypical 
seasonality of the outbreak, during the 
winter in Boston, could be related to 
the unusually mild temperatures in the 
winter of 2012.
Recent CVA6 outbreaks have 
been characterized by a febrile illness 
associated with an oral enanthem 
and lesions on the palms, soles, and 
buttocks. CVA6 infections in Taiwan 
during 2004–2009 were associated 
with HFMD in 13% of cases, with 
disease defi ned as oral ulcers on the 
tongue or buccal mucosa and vesicular 
rashes on the palms, soles, knees, or 
buttocks (2). In Singapore, where 
CVA6 accounted for 24% of HFMD 
cases, patients had oral lesions and <5 
peripheral papules, placing them on 
a spectrum closer to the herpangina 
more typically observed in CVA6 
infection (8).
The patients we report in this 
cluster most typically had perioral 
and perirectal papules in addition to 
vesicles on the dorsum of their hands. 
Two reports of CVA6-associated 
HFMD outbreaks describe cases 
that more closely resemble patients 
in the Boston outbreak. In a series 
from Finland in 2008, representative 
patients had both perioral lesions and 
vesicles on the dorsum of their hands 
(6). In a large series of patients with 
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HFMD in Taiwan in 2010, patients 
with CVA6 had perioral lesions in 
addition to an enanthem (3).
Outbreaks of CVA6-associated 
HFMD in Finland, Taiwan, and Japan 
were associated with onychomadesis, 
with the loss of nails occurring 1–2 
months after initial symptoms (3,4,6). 
The association between more typical 
HFMD and onychomadesis has 
additionally been described in the 
United States and Europe but without 
a link to specifi c serotype or with a 
small percentage of CVA6-associated 
cases (9). Cases from the Boston 
epidemic may fi t into an emerging 
clinical phenotype of CVA6, and it 
will be interesting to see whether nail 
loss develops in those patients.
Given the numerous CVA6 
outbreaks in multiple countries in 
2008 and a US population that may be 
relatively naïve to this serotype, CVA6 
is likely to spread throughout North 
America. Clinicians should be aware 
that, although standard precautions 
are routinely recommended for 
managing enteroviral infections 
in health care settings, contact 
precautions are indicated for children 
in diapers to control institutional 
outbreaks (10). In addition, the 
presence of perioral lesions and 
peripheral vesicles on the dorsum 
rather than palmar/plantar surface of 
the hands and feet represents a unique 
phenotype of HFMD that could be 
confused with herpes simplex or 
varicella-zoster virus infections. 
Because of the atypical presentation 
of CVA6-associated HFMD, clinical 
vigilance is needed to recognize 
emerging regional outbreaks. More 
detailed epidemiologic and genetic 
analyses will be required to 
characterize the role of CVA6 in US 
outbreaks of HFMD.
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Figure. Manifestations of hand, foot, and mouth disease in patients, Boston, Massachusetts, USA, 2012. Discrete superfi cial crusted 
erosions and vesicles symmetrically distributed in the perioral region (A), in the perianal region (B), and on the dorsum of the hands (C). 
A color version of this fi gure is available online (wwwnc.cdc.gov/EID/article/18/10/12-0813-F1.htm).
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vivax infections in 
Humans and Apes, 
Africa
To the Editor: Benign tertian 
malaria, caused by Plasmodium vivax, 
has long been considered absent, or 
at least extremely rare, in western 
and central Africa. In these regions, 
95%–99% of humans are of the Duffy 
negative phenotype, a condition that is 
thought to confer complete protection 
against the parasite during the blood 
stages of its life cycle (1,2). Sporadic 
reports throughout the latter half of the 
20th century, however, have hinted at 
the presence of the parasite in these 
regions, the most convincing of 
which were the steady and consistent 
numbers of non-African travelers who 
returned to their countries of origin 
infected with malarial parasites that 
were subsequently identifi ed as P. 
vivax (2).
More recently, evidence has 
emerged regarding the transmission 
of P. vivax in regions of Africa 
where the local human population is 
predominantly Duffy negative (3–6). 
In 4 (3.5%) of 155 patients from 
western Kenya (6), 7 (0.8%) of 898 
persons from Angola (4), and 8 (8.2%) 
of 97 persons from Equatorial Guinea 
(4), P. vivax parasites were detected 
in the blood of apparently Duffy-
negative persons, suggesting that the 
parasite might not be as absolutely 
dependent on the Duffy receptor for 
erythrocyte invasion as previously 
thought. These fi ndings are supported 
by a report from Madagascar (where 
the human population is composed 
of a mixture of Duffy-positive and 
Duffy-negative persons), in which 42 
(8.8%) of 476 Duffy-negative persons 
who had symptoms of malaria were 
reported to be positive for P. vivax 
by both microscopy and PCR (7). 
The prevalence of P. vivax in Duffy-
negative persons was signifi cantly 
lower than its prevalence in Duffy-
positive persons residing in the same 
area, suggesting that Duffy negativity 
is a barrier to the parasite to some 
degree. Given the extremely high rates 
of malaria transmission in western and 
central Africa, a P. vivax parasite that 
could effi ciently invade Duffy-negative 
erythrocytes would, presumably, 
become highly prevalent very rapidly.
With the exception of the cases 
reported from Angola and Kenya, 
which lie outside the area where 
the proportion of the population 
with Duffy negativity is highest, 
the reports of the transmission of P. 
vivax within predominantly Duffy-
negative populations all come from 
regions inhabited by chimpanzees and 
gorillas (i.e., Democratic Republic 
of the Congo [3], Uganda [4], and 
Equatorial Guinea [5]). During our 
seroepidemiologic study from the 
Democratic Republic of the Congo, 
in which P. vivax sporozoite–specifi c 
antibodies were detected in ≈10% of 
the population, we found that women 
were signifi cantly more likely than 
men to have been exposed to P. vivax 
sporozoites (3). Women in this region 
typically spend more time than men 
near the forest fringe, where they work 
in crop fi elds. This forest is within the 
known habitat range of the chimpanzee 
Pan troglodytes and the gorilla, Gorilla 
gorilla gorilla, both of which have 
been reported to be natural hosts of the 
malaria parasite P. schwetzi, which is a 
P. vivax–like or P. ovale–like parasite 
that might also be unable to invade 
the erythrocytes of persons who are 
Duffy negative (8). These animals have 
recently been shown to be infected 
occasionally with parasites that have 
mitochondrial genomes closely 
resembling those of P. vivax (9,10).
We have argued that, given the 
high malaria transmission rates in sub-
Saharan Africa, it is plausible that the 
1%–5% of the human population who 
are Duffy positive might maintain 
the transmission of the parasite (2). 
The discovery of P. vivax parasites 
(or P. vivax–like parasites) in the 
blood of African great apes leads to 
a question: could nonhuman primates 
in Africa be acting as Duffy-positive 
reservoirs of P. vivax in regions 
where the human population is almost 
entirely insusceptible? This possibility 
warrants further investigation. Given 
the increasing rarity of the great 
apes, however, their capacity to act as 
zoonotic reservoirs could be limited. 
It would be informative, in any case, 
to determine how the regions that P. 
vivax–positive travelers visit during 
their stay in Africa correspond with the 
ranges of chimpanzees and gorillas.
If African great apes do, indeed, 
constitute a zoonotic reservoir of 
P. vivax parasites, what are the 
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